MeiraGTx's AAV-CNGA3 Gets FDA Fast-Track Designation in Achromatopsia
26 Gennaio 2021 - 5:28PM
Dow Jones News
By Colin Kellaher
MeiraGTx Holdings PLC on Tuesday said the U.S. Food and Drug
Administration granted fast-track designation to its AAV-CNGA3
gene-therapy product candidate to treat the retinal disease
achromatopsia caused by mutations in the CNGA3 gene.
The New York clinical-stage biotechnology company said it is
currently conducting an open-label, dose-escalation Phase 1/2
clinical trial of AAV-CNGA3, which it is developing as part of a
collaboration with Johnson & Johnson's Janssen Pharmaceuticals
Inc. unit aimed at the treatment of inherited retinal diseases.
The FDA's fast-track program is designed to facilitate the
development and expedite the review of treatments for serious or
potentially life-threatening illnesses with high unmet medical
needs. The agency previously granted orphan-drug designation to
AAV-CNGA3 and has designated it as a drug for a rare pediatric
disease.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 26, 2021 11:13 ET (16:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Johnson and Johnson (NYSE:JNJ)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Johnson and Johnson (NYSE:JNJ)
Storico
Da Apr 2023 a Apr 2024